An expert from the company discusses how ever-changing patient needs and other dynamic factors are likely to impact pharma ingredient trends down the road.
Leaders from some of the industry’s most notable companies are working together to streamline and automate IDMP workflow and come up with various standards.
The company’s Mavenclad treatment gains approval from the US FDA for the treatment of multiple sclerosis, eight years after it had been initially rejected.
Merck KGaA has announced a plan to close some EU production sites and invest in others, citing the centralization strategy employed by Sigma-Aldrich as inspiration.
Solvias has struck a deal with Germany’s Merck to supply a monocyte activation test (MAT) kit for detecting pyrogens in pharmaceutical raw ingredients.
New acquisition Sigma Aldrich will play a part in African growth plans in addition to giving it a presence in the preclinical services sector says Merck*.
Attaching PEG-chains to biological molecules can increase bioavailability and speed up development of protein-based therapies and biosimilars, says EMD Millipore which has inked a deal with PEGylation firm celares.
Patients and pharmacists can now use smartphones to check biologics are genuine with a new Merck Serono tech launched to combat counterfeiters' growing interest in high-value biopharma drugs.
The acquisition of Sigma-Aldrich by Merck KGaA could provide some opportunities for Johnson Matthey, the fine chemical company says as it reports a flat first half 2014/15.
Life science sector consolidation is a concern for some biomanufacturers, who say mega mergers like Merck KGaA’s $17bn acquisition of Sigma-Aldrich will limit their ability to negotiate on prices.
Novo Nordisk is reportedly searching for obesity experts to staff an R&D centre, Merck Serono gets a new CEO, and we look at the latest biopharmaceutical hires.
Strategic partnerships - always a hot-topic for CROs – are becoming almost exclusively a big issue for mid-sized biopharma, though small biopharma and large pharma companies are interested as well, Quintiles CEO Tom Pike said Monday at the Morgan Stanley...
Biopharmaceutical firm Merck Serono will make small molecule drugs at the new plant it is building in China according to a company spokeswoman, who told us the firm will supply both local and international markets.
Merck Millipore, the life science division of Merck KGaA, will invest €12m ($16m) at its Molsheim, France facility to expand its ready-to-use media manufacturing capabilities and capacity.
Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.
Big Pharma's split opinion on the best way to work with a CRO was in evidence in Las Vegas this week with Pfizer underlining its commitment to strategic deals and Merck KGaA backing a multi-vendor model.
The team behind the scheme that helped BASF, Seppic and Merck KGaA reduce their audit burdens expect more excipient suppliers to seek certification as an independent association.
A French subsidiary of specialty ingredients firm Seppic has become the latest supplier certified under the Excipact quality scheme for drug excipients
CEO Tom Pike emphasised Quintiles’ credentials as a Big Pharma collaborator and highlighted personalised medicines as a key driver for the CRO at an investment conference last week.
Trust, transparency and end-to-end participation are just some of the reasons Merck Serono says its exclusive strategic partnership with Quintiles is the “first of its kind.”
Janet Woodcock is set to stay at the CDER despite rumours of her retirement, and there's a host of new appointments at Merck Serono - welcome to in-Pharmatechnologist's People on the Move.
Johnson & Johnson has reorganised its Chinese divisions under one Chairman, and Merck KGaA has a new CIO - welcome to in-Pharmatechnologist's People on the Move.
EMD Millipore says while voluntary excipient quality schemes are step in the right direction, formal GMP and enforcement would create a level playing field.
Merck Serono says “fast progress” in its restructure programme helped double its net savings guidance for 2012 though headcount dropped by almost 2,000 with more cuts to come.
Outsourcing-Pharma.com presents its latest round up of career moves in the pharmaceutical industry, including news from Theorem, FMC Technologies and EMD Serono.
Biosimilars should help Millipore achieve long-term growth but cancellation of an insulin contract and rising raw material costs hit second quarter results.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Sanofi Pasteur, Klöckner Pentaplast and Geron.
